Literature DB >> 15739028

Prediction of radiation pneumonitis: dose-volume histogram analysis in 62 patients with non-small cell lung cancer after three-dimensional conformal radiotherapy.

T Piotrowski1, M Matecka-Nowak, P Milecki.   

Abstract

The purpose of the study was to determine the relation between the incidence of radiation pneumonitis (RP) and available parameters from a dose-volume histogram (DVH) in patients with non-small cell lung cancer (NSCLC) who underwent three-dimensional conformal radiotherapy treatment. Between January 1999 and August 2003 in the Greatpoland Cancer Center, 62 patients with NSCLC were treated using three-dimensional conformal radiotherapy (3D CRT). All patients were treated 5 days per week with daily fractionation of 2 Gy to total dose of 60 Gy. All patients were available for analysis for symptomatic RP. Radiation pneumonitis was graded according to the RTOG/EORTC morbidity scoring classification. Logistic regression analysis was performed to test the association between RP and the following DVH parameters: mean lung dose (MLD), volume of lung receiving > or =20 Gy (V20 ) and > or =30 Gy (V30) and normal tissue complication probability (NTCP). Additionally, correlation of the following clinical factors such as: age, sex, tumor site, performance status (KPS), and additional therapy (chemotherapy) with incidence of the RP were performed. Moreover, correlation between DVH parameters were tested using Spearman method. Thirty out of 62 patients (48%) developed RP grade 0 or 1 (0 grade -- 12%, 1 grade -- 36%) and 32 (52%) grade 2 or 3 (2 grade -- 47%, 3 grade -- 5%). In the logistic regression analysis, all DVH parameters were associated with RP (p in range from 0.004 to 0.007). The strongest association was observed for NTCP and V30 (p=0.004). On the other hand, a weak association was found for V20 (p=0.007). The correlations between all DVH parameters for lung were sufficient (r Spearman in range from 0.87 to 0.93). The best correlation among DVH parameters were observed between V20 and NTCP (r=0.93, p<0.001). On the other hand, the least but sufficient association was found for V30 and V20 (r=0.87, p<0.001). There was no association between clinical factors and RP. NTCP and V30 parameters were the best predictors of symptomatic radiation pneumonitis for patients after three-dimensional conformal radiotherapy of non-small cell lung cancer.

Entities:  

Mesh:

Year:  2005        PMID: 15739028

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  8 in total

Review 1.  Radiation dose-volume effects in the lung.

Authors:  Lawrence B Marks; Soren M Bentzen; Joseph O Deasy; Feng-Ming Spring Kong; Jeffrey D Bradley; Ivan S Vogelius; Issam El Naqa; Jessica L Hubbs; Joos V Lebesque; Robert D Timmerman; Mary K Martel; Andrew Jackson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

2.  Functional dose-volume histograms for predicting radiation pneumonitis in locally advanced non-small cell lung cancer treated with late-course accelerated hyperfractionated radiotherapy.

Authors:  Dongqing Wang; Baosheng Li; Zhongtang Wang; Jian Zhu; Hongfu Sun; Jian Zhang; Yong Yin
Journal:  Exp Ther Med       Date:  2011-06-29       Impact factor: 2.447

Review 3.  Prediction of radiation pneumonitis in lung cancer patients: a systematic review.

Authors:  Xiao-Jing Zhang; Jian-Guo Sun; Jie Sun; Hua Ming; Xin-Xin Wang; Lei Wu; Zheng-Tang Chen
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-29       Impact factor: 4.553

4.  Analysis of related factors associated with radiation pneumonitis in patients with locally advanced non-small-cell lung cancer treated with three-dimensional conformal radiotherapy.

Authors:  Jun Dang; Guang Li; Xiaobe Lu; Lei Yao; Shuo Zhang; Zhan Yu
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-04       Impact factor: 4.553

5.  Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer.

Authors:  Satoshi Saito; Takanori Abe; Nao Kobayashi; Tomomi Aoshika; Yasuhiro Ryuno; Mitsunobu Igari; Ryuta Hirai; Yu Kumazaki; Yu Miura; Kyoichi Kaira; Hiroshi Kagamu; Shin-Ei Noda; Shingo Kato
Journal:  Clin Transl Radiat Oncol       Date:  2020-05-30

6.  Risk factor of pneumonitis on dose-volume relationship for chemoradiotherapy with durvalumab: Multi-institutional research in Japan.

Authors:  Yoshiko Oshiro; Masashi Mizumoto; Yuta Sekino; Kazushi Maruo; Toshiki Ishida; Taisuke Sumiya; Masatoshi Nakamura; Ayako Ohkawa; Daichi Takizawa; Toshiyuki Okumura; Yoshio Tamaki; Hideyuki Sakurai
Journal:  Clin Transl Radiat Oncol       Date:  2021-05-29

7.  Helical and Static-port Tomotherapy Using the Newly-developed Dynamic Jaws Technology for Lung Cancer.

Authors:  Yoshihiko Manabe; Yuta Shibamoto; Chikao Sugie; Akihiro Hayashi; Taro Murai; Takeshi Yanagi
Journal:  Technol Cancer Res Treat       Date:  2014-11-26

8.  Reducing dose to the lungs through loosing target dose homogeneity requirement for radiotherapy of non small cell lung cancer.

Authors:  Junjie Miao; Hui Yan; Yuan Tian; Pan Ma; Zhiqiang Liu; Minghui Li; Wenting Ren; Jiayun Chen; Ye Zhang; Jianrong Dai
Journal:  J Appl Clin Med Phys       Date:  2017-10-11       Impact factor: 2.102

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.